AOD-9604 is a synthetic modified fragment of human growth hormone (hGH), specifically designed for lipolytic (fat metabolism) research. Originally studied for its potential role in obesity-related research, AOD-9604 has been investigated for its ability to stimulate fat breakdown (lipolysis) while reducing fat accumulation (lipogenesis).
Unlike full-length hGH, AOD-9604 does not stimulate IGF-1 levels, making it an area of interest in metabolic and weight-regulation research. Studies suggest that this peptide may be a useful tool in examining fat metabolism, energy expenditure, and potential regenerative properties.
While most AOD-9604 studies focus on subcutaneous injection, emerging data suggests that intranasal administration may offer a viable alternative for peptide absorption. Nasal delivery of peptides has been explored in various research models due to its potential for:
Although AOD-9604 nasal delivery has not been as extensively studied as injection-based methods, other peptides have demonstrated promising absorption rates via this route. Further clinical and preclinical research is needed to establish bioavailability, stability, and efficacy when administered nasally.
AOD-9604 is a C-terminal fragment of hGH (amino acids 176-191) and retains the ability to activate beta-3 adrenergic receptors, which are involved in fat oxidation and thermogenesis. Research suggests that this peptide:
AOD-9604 is currently being examined in various preclinical and clinical studies related to:
AOD-9604 is intended for research purposes only. It is not for human consumption, medical use, or diagnostic applications. All information presented is for scientific and educational research.
LP10 FOR 10% OFF YOUR ORDER